Navigation Links
InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
Date:2/26/2009

MN-191 were accrued and payment to Roche was deferred. This $11.4 million payment will be made to Roche in 2009.

InterMune will make a scheduled Department of Justice (DOJ) payment of approximately $7.0 million in 2009. Additionally, the company anticipates that it may be required to make an accelerated payment to the DOJ of approximately $4.4 million related to the company's recent financing event. If both of these DOJ payments are made, the balance of the Liability Under Government Settlement would be approximately $13.2 million as of December 31, 2009.

Conference Call and Webcast Details

InterMune will host a conference call today at 4:30 p.m. EST to discuss its financial results for the fourth quarter and full year 2008, and its forward-looking financial guidance. Interested investors and others may participate in the conference call by dialing 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 86755415. A replay of the webcast and teleconference will be available approximately three hours after the call.

To access the webcast, please log on to the company's website at http://www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 86755415. The webcast will remain available on the company's website until the next earnings call.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
2. InterMune Announces Issuance of U.S. Patent for ITMN-191
3. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
4. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
5. InterMune to Present at J.P. Morgan Healthcare Conference
6. InterMune to Present at Deutsche Bank Biotech Boston Confab
7. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
8. InterMune to Release Third Quarter 2008 Financial Results on November 6
9. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
10. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
11. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , ... July 27, 2015 , ... ... of the Biophotonics industry.The report provides a basic overview of the industry including ... for the international markets including development trends, competitive landscape analysis, and key regions ...
(Date:7/27/2015)... MONTREAL , July 27, 2015   ... that produces sustainable biological accelerators for farmers, has ... Patent and Trademark Office for its patent application ... that accelerate plant growth and enhance yields on ... patent relates to Inocucor,s live IN-M1 microbial consortium ...
(Date:7/27/2015)... WORTH, Texas , July 27, 2015 ... Media Market by Type (Home-brew Media, Pre-formulated Media), by Application ... America , Europe , ... Forecast to 2019", The global biopreservation media market was valued ... to around $571.5 million by 2019, at a CAGR of ...
(Date:7/27/2015)... , July 27, 2015 IDEXX Laboratories, Inc. ... 8,000 clinics have submitted over 100,000 specimens to IDEXX ... just the first 10 days since the breakthrough kidney ... (CKD) is a leading cause of suffering and death ... specimens are consistent with generally accepted kidney disease prevalence ...
Breaking Biology Technology:2015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 2Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 4Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 5
... SAN DIEGO, March 30 BrainCells Inc. (BCI), ... using its proprietary platform technology to identify novel ... today the appointment of Dr. Philip Jochelson as ... business officer. Both have extensive experience in the ...
... informed consent software for clinical research trials has named Jovianna ... over 20 years experience driving new pharmaceutical therapeutics and devices ... clinical development to commercialization. , ... ...
... ITMN ) today announced that Daniel G. Welch, ... at Citi,s 4th Annual Biotech Day in New York City ... access a live audio webcast of the presentation, investors and ... page of InterMune,s corporate website at www.intermune.com . ...
Cached Biology Technology:BrainCells Inc. Appoints Philip Jochelson, M.D. Chief Medical Officer and Jason Levin Chief Business Officer 2BrainCells Inc. Appoints Philip Jochelson, M.D. Chief Medical Officer and Jason Levin Chief Business Officer 3Jovianna DiCarlo Named ConsentSolutions, Inc. President & Chief Executive Officer 2
(Date:6/29/2015)... 2015 Research and Markets( ... "Latin America Biomedical Sensors Market - Growth, Trends & ... The Latin America Biomedical Sensors market is estimated at ... over the period 2014-2020 The near future ... genetic formulation of each individual. These sensors can be ...
(Date:6/25/2015)... According to a new ... Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive & ... Others) & Geography - Global Forecast to 2014 ... is expected to reach $14,500.07 Million by 2020, ... Browse 76 market Tables and 109 Figures spread ...
(Date:6/25/2015)... N.J. , June 25, 2015  TAKE Solutions ... a patent by the United States Patent and Trademark ... Standardization". This process leverages TAKE Solutions, Clinical Accelerators to ... over 50% (when compared to standardization without the accelerators), ... At the heart of ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2
... BOZEMAN Two Montana state University researchers are principal ... find noninvasive ways to study carnivores in the wild. ... was released June 27 with Robert Long and Paula ... at MSU,s Western Transportation Institute. Working with ...
... has shown that enhancing the production of a protein ... neuron death associated with Alzheimer,s, at the expense of ... amyloid-beta protein plaques within the brain is a major ... contribute to disease progression. Normally, special enzymes chew up ...
... type of probe that can image thousands of interactions ... tool to untangle the web of signaling pathways that ... use this to identify new protein partners or to ... the proteins are involved in and during which phase ...
Cached Biology News: